Estimated 48% of Women with Heavily Treated Ovarian Cancer Were Alive at Three Years in Small Immunotherapy Trial
An early trial of botensilimab plus balstilimab showed an estimated 48% three-year survival rate in recurrent ovarian cancer. Here is what the data mean.
Medical Daily ·